This phase I/II trial is evaluating a new type of immunotherapy, known as a neoantigen cancer vaccine, in combination with two established immunotherapies, as a treatment for several different types of cancerAn International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors

Inclusion

• Provide a signed and dated informed consent form prior to initiation of study-specific procedures.

• Patients with the indicated advanced or metastatic solid tumor as follows:

  1. NSCLC who are planned for or have received no more than 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy (note: patients who have received anti-PD-(L)1 monotherapy are eligible)
  2. GEA who are planned for or have received no more than 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
  3. mUC who are planned for or have received no more than 1 cycle of systemic treatment with cytotoxic, platinum-based chemotherapy
  4. CRC-MSS who are receiving first line systemic therapy or who are planned for or have received no more than 1 cycle of second line systemic therapy including a fluoropyrimidine and oxaliplatin or irinotecan
• 18 years of age or older
• ECOG Performance Status 0 or 1
• Lesion amenable to biopsy
• Measurable disease according to RECIST v1.1
• Have adequate organ function, as measured by laboratory values (criteria listed in protocol)